A peripheral-blood smear reportedly showed schistocytes. After consultation with the hematology service was obtained, fresh-frozen plasma and packed red cells were transfused, and intravenous ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Senators questioned Mehmet Oz, MD, MBA, on Medicaid budget cuts, nursing shortages and his prior claims about miracle drugs during a committee hearing to be the next administrator of CMS ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window These are ...

Please provide your email address to receive an email when new articles are posted on . It’s been a busy first quarter here at Healio Community. Since our launch in January, the team has been ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug reduced blood procedures among patients with a rare type of cancer in a ...

He’s got new blood. A Long Island hospital said it administered life-changing Lyfgenia gene therapy treatment and successfully wiped away sickle cell disease from a Laurelton man. Cohen Children ...

A renowned medical school whose faculty helped treat a young cancer survivor honored this week by President Donald Trump is facing potentially devastating funding cuts because of the White House.

Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

States must analyze the data on Medicaid and social determinant programs to understand the consequences of how potential policy changes will impact residents, Molly Dean, MSW, Siftwell, explains ...

Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...